TrialCurvePORTEC-3: reconstructed Kaplan–Meier curves
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. 2025 Oct;26(10):1370–81. doi: 10.1016/S1470-2045(25)00379-1 |
|---|---|
| DOI | 10.1016/S1470-2045(25)00379-1 |
| Registry | NCT00411138 |
| Phase | Phase 3 |
| Conditions | Endometrial Cancer |
| Interventions | Radiation Therapy, cisplatin, carboplatin, Paclitaxel |
| Sponsor | Leiden University |
| Enrolment | 670 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — All patients, by treatment group
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Chemoradiotherapy not reached; Radiotherapy alone not reached. Survival at 2 years: Chemoradiotherapy 90%; Radiotherapy alone 91%. Hazard ratio Chemoradiotherapy vs Radiotherapy alone 0.80 (95% CI 0.59–1.07).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Chemoradiotherapy | 330 | 80 | not reached |
| Radiotherapy alone | 330 | 101 | not reached |
- Chemoradiotherapy vs Radiotherapy alone: reconstructed HR 0.80 (95% CI 0.59–1.07)
Landmark survival (reconstructed)
| Time | Chemoradiotherapy | Radiotherapy alone |
|---|---|---|
| 1 yr | 95.7% | 97.3% |
| 2 yr | 89.6% | 90.6% |
| 3 yr | 84.4% | 83.3% |
| 5 yr | 81.3% | 76.5% |
| 7 yr | 78.5% | 73.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.73, reconstructed 0.799 pass
Recurrence-free survival — All patients, by treatment group
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Radiotherapy alone not reached; Chemoradiotherapy not reached. Survival at 3 years: Radiotherapy alone 72%; Chemoradiotherapy 80%. Hazard ratio Chemoradiotherapy vs Radiotherapy alone 0.77 (95% CI 0.58–1.03).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Radiotherapy alone | 330 | 107 | not reached |
| Chemoradiotherapy | 330 | 87 | not reached |
- Chemoradiotherapy vs Radiotherapy alone: reconstructed HR 0.77 (95% CI 0.58–1.03)
Landmark survival (reconstructed)
| Time | Radiotherapy alone | Chemoradiotherapy |
|---|---|---|
| 1 yr | 87.9% | 92.7% |
| 2 yr | 78.2% | 84.4% |
| 3 yr | 72.1% | 80.3% |
| 5 yr | 69.6% | 76.8% |
| 7 yr | 68.3% | 73.2% |
| 10 yr | 67.2% | 72.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.74, reconstructed 0.773 pass
Overall survival — By molecular group (both treatment groups combined)
From figure panel C · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: POLEmut not reached; NSMP not reached; MMRd not reached; p53abn 7.2 years. Survival at 3 years: POLEmut 98%; NSMP 93%; MMRd 86%; p53abn 67%. Hazard ratio POLEmut vs p53abn 0.03 (95% CI 0.00–0.19).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| POLEmut | 51 | 1 | not reached |
| NSMP | 122 | 26 | not reached |
| MMRd | 139 | 35 | not reached |
| p53abn | 99 | 54 | 7.2 |
- POLEmut vs p53abn: reconstructed HR 0.03 (95% CI 0.00–0.19)
- NSMP vs p53abn: reconstructed HR 0.29 (95% CI 0.18–0.47)
- MMRd vs p53abn: reconstructed HR 0.38 (95% CI 0.25–0.58)
Landmark survival (reconstructed)
| Time | POLEmut | NSMP | MMRd | p53abn |
|---|---|---|---|---|
| 1 yr | 100.0% | 95.9% | 99.3% | 93.9% |
| 2 yr | 98.0% | 95.1% | 93.5% | 76.8% |
| 3 yr | 98.0% | 93.4% | 86.2% | 66.7% |
| 5 yr | 98.0% | 89.3% | 81.8% | 55.6% |
| 7 yr | 98.0% | 85.1% | 78.0% | 52.5% |
| 10 yr | 98.0% | — | — | — |
Recurrence-free survival — By molecular group (both treatment groups combined)
From figure panel D · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: POLEmut not reached; MMRd not reached; NSMP not reached; p53abn 4.9 years. Survival at 3 years: POLEmut 98%; MMRd 78%; NSMP 82%; p53abn 55%. Hazard ratio POLEmut vs p53abn 0.03 (95% CI 0.00–0.18).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| POLEmut | 51 | 1 | not reached |
| MMRd | 139 | 35 | not reached |
| NSMP | 122 | 39 | not reached |
| p53abn | 99 | 54 | 4.9 |
- POLEmut vs p53abn: reconstructed HR 0.03 (95% CI 0.00–0.18)
- MMRd vs p53abn: reconstructed HR 0.39 (95% CI 0.25–0.59)
- NSMP vs p53abn: reconstructed HR 0.45 (95% CI 0.30–0.68)
Landmark survival (reconstructed)
| Time | POLEmut | MMRd | NSMP | p53abn |
|---|---|---|---|---|
| 1 yr | 98.0% | 90.6% | 94.3% | 81.8% |
| 2 yr | 98.0% | 81.2% | 87.7% | 63.5% |
| 3 yr | 98.0% | 77.6% | 82.0% | 55.3% |
| 5 yr | 98.0% | 74.6% | 76.1% | 49.0% |
| 7 yr | 98.0% | 74.6% | 69.3% | 45.9% |
| 10 yr | 98.0% | — | — | — |
Overall survival — MMRd cancer
From figure panel E · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Radiotherapy alone not reached; Chemoradiotherapy not reached. Survival at 3 years: Radiotherapy alone 90%; Chemoradiotherapy 82%. Hazard ratio Radiotherapy alone vs Chemoradiotherapy 0.69 (95% CI 0.35–1.37).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Radiotherapy alone | 72 | 15 | not reached |
| Chemoradiotherapy | 67 | 19 | not reached |
- Radiotherapy alone vs Chemoradiotherapy: reconstructed HR 0.69 (95% CI 0.35–1.37)
Landmark survival (reconstructed)
| Time | Radiotherapy alone | Chemoradiotherapy |
|---|---|---|
| 1 yr | 98.6% | 100.0% |
| 2 yr | 94.4% | 92.4% |
| 3 yr | 90.3% | 81.8% |
| 5 yr | 84.7% | 78.7% |
| 7 yr | 81.8% | 73.8% |
| 10 yr | 78.2% | 69.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.34, reconstructed 1.44 pass
Recurrence-free survival — MMRd cancer
From figure panel F · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Radiotherapy alone not reached; Chemoradiotherapy not reached. Survival at 3 years: Radiotherapy alone 78%; Chemoradiotherapy 77%. Hazard ratio Radiotherapy alone vs Chemoradiotherapy 0.85 (95% CI 0.44–1.66).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Radiotherapy alone | 72 | 17 | not reached |
| Chemoradiotherapy | 67 | 18 | not reached |
- Radiotherapy alone vs Chemoradiotherapy: reconstructed HR 0.85 (95% CI 0.44–1.66)
Landmark survival (reconstructed)
| Time | Radiotherapy alone | Chemoradiotherapy |
|---|---|---|
| 1 yr | 90.3% | 91.0% |
| 2 yr | 83.3% | 78.9% |
| 3 yr | 77.8% | 77.4% |
| 5 yr | 76.3% | 72.6% |
| 7 yr | 76.3% | 72.6% |
| 10 yr | 76.3% | 72.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.13, reconstructed 1.17 pass
Overall survival — NSMP cancer
From figure panel G · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Radiotherapy alone not reached; Chemoradiotherapy not reached. Survival at 3 years: Radiotherapy alone 91%; Chemoradiotherapy 96%. Hazard ratio Chemoradiotherapy vs Radiotherapy alone 0.66 (95% CI 0.30–1.47).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Radiotherapy alone | 55 | 13 | not reached |
| Chemoradiotherapy | 67 | 11 | not reached |
- Chemoradiotherapy vs Radiotherapy alone: reconstructed HR 0.66 (95% CI 0.30–1.47)
Landmark survival (reconstructed)
| Time | Radiotherapy alone | Chemoradiotherapy |
|---|---|---|
| 1 yr | 94.5% | 97.0% |
| 2 yr | 94.5% | 95.5% |
| 3 yr | 90.9% | 95.5% |
| 5 yr | 87.3% | 90.9% |
| 7 yr | 81.8% | 87.8% |
| 10 yr | 74.1% | 81.8% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.6, reconstructed 0.66 pass
Recurrence-free survival — NSMP cancer
From figure panel H · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Radiotherapy alone not reached; Chemoradiotherapy not reached. Survival at 3 years: Radiotherapy alone 75%; Chemoradiotherapy 88%. Hazard ratio Chemoradiotherapy vs Radiotherapy alone 0.64 (95% CI 0.34–1.20).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Radiotherapy alone | 55 | 21 | not reached |
| Chemoradiotherapy | 67 | 18 | not reached |
- Chemoradiotherapy vs Radiotherapy alone: reconstructed HR 0.64 (95% CI 0.34–1.20)
Landmark survival (reconstructed)
| Time | Radiotherapy alone | Chemoradiotherapy |
|---|---|---|
| 1 yr | 92.7% | 95.5% |
| 2 yr | 81.8% | 91.0% |
| 3 yr | 74.5% | 88.1% |
| 5 yr | 67.3% | 83.4% |
| 7 yr | 65.5% | 72.2% |
| 10 yr | 61.1% | 72.2% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.61, reconstructed 0.64 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- Chemoradiotherapy ± simultaneous integrated boost in cervical cancer: Overall survival; Pelvic-specific PFS; Progression-free survival (PFS)
- SCORES: Overall survival; Overall survival, final analysis
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials